>>> What to look at today - 19th of May 2015

Dow+0,14% S&P+0,30% Nasdaq+0,60% Russell+1,09%
US Market closed slightly higher with tech higher...Dow & S&P registered new records...AAPL (on Icahn letter) & Altera (Intel potential deal) helped the all sector to perform...M&A also helped with ANN offer (21,4% premium) and Endo buying Par Pharma. Volume were below average at 700m shares...S&P500 hit new record highs while Treasuries fell, reversing some of the gains made on Friday. Some of the focus fell on the research paper from the San Francisco Fed, putting the post-adjustment US Q1 GDP around 1.8% rather than 0.2% as reported by the Commerce Dept. SF Fed also indicated that much of the Q1 weakness could be attributed to seasonality of adverse weather, implying the worries about the timing of Fed rate hikes after last week's soft US data may be overdone. VIX @ 12.73 +2,83%...US After Hours GIGA +24.4%, MOMO +21.5%, TTWO +7.4%, URBN -15.3%, AMCN -3.8%, A -3.1% following earnings/guidance...Asia's main indices are higher nearly across the board, tracking a session of modest gains in the US hours. Shanghai Composite was the clear outperformer, rising over 1% in the opening hour and then zooming to 2.7% rise entering its lunch break. Note the index was down for the past 2 sessions, and there's chatter the high-margin speculative buying is behind today's move. Investors are also reacting positively to China State Council unveiling its 2015 economic reform, pledging to focus on economic growth, deregulate central power, promote FX convertibility, loosen control of investment and boost reforms of SOE in key industries such as electricity.

Nikkei +0.84% Hang Seng +0.25% Shanghai +2.46%

Eur$ 1.1318 RUB $49.03 EURCHF 1.0482 GBP 1.5666 CHF 0.9260 WTI $59.52 (+0.52%)

S&P +0.09% EuroStoxx Dax SMI


Macro :
- Greek Bailout Negotiations in Final Stage, PM Tsipras Says
- ECB Wouldn’t Cut ELA If Greece Misses IMF Payment: Handelsblatt
- Oil Price Drop Puts More Than $100b of Projects on Hold, FT Says
- EU Autos Still Show Most Upside Despite YTD Gain as PTs Increase
- EU28 April Car Registrations Rise 6.9% Y/y to 1.166m Units

Keep an eye on :
- ABE FP : Abertis Says Cellnex Greenshoe Option Exercised
- AREVA FP : EDF Wants Control of Areva Reactor Business, Levy Tells Figaro
- AVV LN : Aveva FY15 Adj. Pretax, EPS Beat Estimates; Revenue In Line
- POP SM : Spain’s Banco Popular Seeking Acquisitions Abroad: WSJ
- CLNX SM : Cellnex Wants to Triple Its Size, CEO Martinez Tells Expansion
- CERV IM : CVC Selling 29m Shrs of Cerved in Bookbuilding, Cerved Shr Sale Increased to 32m Shrs: Terms --> Priced @ €6.35/sh.
- CON GY : Elektrobit Sells Automotive Business to Continental for EU600m
- DL NA : Delta Lloyd 1Q Solvency Ratio Rises to 208%; Premiums Increase
- DBK GY : Deutsche Bank Seen Reviewing Moving Part of UK Ops to Germany:FT
- DPW GY : Deutsche Postbank Chairman Neske to Leave, Handelsblatt Reports
- DUFN SW : Dufry Offers Early Conversion of Up to CHF275m Convertible
- EXAE GA : Hellenic Exchanges Posts 1Q Net Income of EU4.1m Vs EU4.8m
- JEN BB : Jensen-Group 1Q Rev. Rises 34% on FX; Profitability Seen In Line
- BAER VX : Julius Baer End-April AUM Falls 1% From End 2014 to CHF289b
- LEAS BB : Leasinvest RE 1Q Adj. EPS Drops to EU1.13; Forecasts Maintained
- MB IM : Bollore Raised Stake Further in Mediobanca, Corriere Reports
- MONY LN : Moneysupermarket.com Founder Nixon Selling Shrs in Bookbuilding
- NOK1V FH : Uber Joins Baidu as Nokia’s Maps Unit Draws Multiple Bidders
- NOVOB DC : Novo Faces U.S. ITC Section 337 Probe After Baxter Request
- ROG VX : Illumina Files Patent Infringement Suit vs Roche’s Ariosa
- ROG VX : Roche Gets FDA CLIA Waiver for Cobas Liat PCR System, Strep A
- S32 LN : South32 Jumps on 2nd Day of Trading; Best Performer on ASX Index
- SAN FP : Regeneron, Sanofi Starting Phase 3 Study of Dupilumab in Asthma
- SEM AV : Semperit 1Q Ebit Rises 8.3% to EU20.1m; Confirms 2015 Targets
- SRP LN : Serco's sale of BPO arm may be delayed over valuation - The Economic Times http://bit.ly/1LfUJKV
- SOON VX : Sonova FY Ebita In Line With Ests., Div. Misses BDVD Forecast
- SRCG SW : Sunrise Communications 1Q Sales, Adj. Ebitda Grow; Posts Loss
- TOM2 NA : Tomtom Extends Global Pact w/ Apple for Maps; No Details Given
- UBER IPO : Dutch Govt Raises Uber Fine Ceiling to EU1m
- UTDI GY : United Internet 1Q Ebitda Misses Ests.; Keeps 2015 Outlook
- VK FP : Vallourec in talks with Ascometal about sale of Saint-Saulve steel mill – Le Echos
- VOD LN : Vodafone 4Q Organic Service Revenue Grows 0.1%
- ZAG AV : Zumtobel 2015 Profit Rises 40% After Revenue Hits Record EU1.3b

>>> Europe : Brokers Upgrades & Downgrades - 19th of May 2015

>>> Up
*AL NOOR HOSPITALS RAISED TO BUY VS HOLD AT HSBC
*CARLSBERG RAISED TO ACCUMULATE VS NEUTRAL AT MIRABAUD
*EIFFAGE RAISED TO OVERWEIGHT VS NEUTRAL AT JPMORGAN
*H&R RAISED TO HOLD VS SELL AT BANKHAUS LAMPE
*REED ELSEVIER RAISED TO BUY VS NEUTRAL AT GOLDMAN
*SKANSKA RAISED TO HOLD VS REDUCE AT HSBC
*VINCI RAISED TO OVERWEIGHT VS NEUTRAL AT JPMORGAN


>>> Down
*ATLANTIA CUT TO NEUTRAL VS OVERWEIGHT AT JPMORGAN
*BHP BILLITON CUT TO REDUCE VS HOLD AT HSBC
*BRENNTAG CUT TO UNDERPERFORM AT CREDIT SUISSE
*HSBC CUT TO MARKET PERFORM AT BERNSTEIN, PT 650P, HK$80
*MITCHELLS & BUTLERS CUT TO HOLD AT JEFFERIES
*XEROS TECHNOLOGY CUT TO UNDERPERFORM VS BUY AT JEFFERIES

>>> PT Change
*CENTRICA PT RAISED from 292 to 305 AT GS
*ITV PT RASIED FROM 294 TO 304 AT GS
*LAGARDERE PT RAISED FROM 26.20 TO 27 AT GS
*MEDISAET ESPANA PT RAISED FROM 11 TO 11.50 AT GS
*REED ELSEVIER PT RAISED FROM 22.90 TO 25.60 AT GS
*SABMILLER CUT TO UNDERPERFORM VS SECTOR PERFORM AT RBC
*SALVATORE FERRAGAMO PT RAISED FROM 34.10 TO 35 AT GS

>>> Initiation
*LENTA RATED NEW OVERWEIGHT AT BARCLAYS, PT $12.43

>>> Call
>> Stock
*FERRAGAMO EXITS GOLDMAN CONVICTION BUY LIST, STAYS BUY
*RICHEMONT ADDED TO CONVICTION BUY LIST AT GOLDMAN

>>> Asian Update

Asian Mid-session Update: Shanghai Composite zooms; RBA minutes imply continued easing bias


***Economic Data***
- (NZ) NEW ZEALAND Q2 2-YEAR INFLATION EXPECTATION: 1.85% V 1.80% PRIOR; 1-YEAR EXPECTATION: 1.32% V 1.11% PRIOR
- (NZ) NEW ZEALAND Q1 PPI OUTPUT Q/Q: -0.9% V -0.1% PRIOR; PPI INPUT Q/Q: -1.1% V -0.4% PRIOR
- (NZ) NEW ZEALAND APR ANZ JOB ADVERTISEMENTS M/M: -0.2% V -0.7% PRIOR; 2nd straight decline
- (AU) Australia Mar Conference Board Leading index m/m: -0.1% v 0.5% prior; first decline in 4 months
- (AU) Australia ANZ Roy Morgan Weekly Consumer Confidence Index: 114.6 v 110.6 prior; Highest since Nov 2014
- (KR) South Korea Apr PPI Y/Y: -3.6% v -3.7% prior; 9th consecutive month of decline

***Index Snapshot (as of 02:30 GMT)***
- Nikkei225 +0.6%, S&P/ASX -0.1%, Kospi +0.4%, Shanghai Composite +1.9%, Hang Seng +0.2%, Jun S&P500 +0.1% at 2,128

***Commodities/Fixed Income***
- Jun gold -0.5% at $1,221/oz, Jul crude oil -0.1% at $60.21/brl, Jul copper flat at $2.91/lb
- GLD: SPDR Gold Trust ETF daily holdings fall 5.5 tonnes to 718.2 tonnes; lowest since Jan 15th
- SLV: iShares Silver Trust ETF daily holdings fall to 9,888 from 9,925; multi-month lows
- (CN) PBoC won't conduct open market operations (OMO) in today's session (9th consecutive halt)
- JGB: (JP) Japan MoF sells ¥2.30T in 0.1% (0.1% prior) 5-yr bonds; Avg yield: 0.10% v 0.081% prior; Bid-to-cover: 2.80x v 3.38x prior

***Market Focal Points/FX***
- Asia's main indices are higher nearly across the board, tracking a session of modest gains in the US hours. S&P500 hit new record highs while Treasuries fell, reversing some of the gains made on Friday. Some of the focus fell on the research paper from the San Francisco Fed, putting the post-adjustment US Q1 GDP around 1.8% rather than 0.2% as reported by the Commerce Dept. SF Fed also indicated that much of the Q1 weakness could be attributed to seasonality of adverse weather, implying the worries about the timing of Fed rate hikes after last week's soft US data may be overdone.

- Shanghai Composite was the clear outperformer, rising over 1% in the opening hour and then zooming to 2.7% rise entering its lunch break. Note the index was down for the past 2 sessions, and there's chatter the high-margin speculative buying is behind today's move. Investors are also reacting positively to China State Council unveiling its 2015 economic reform, pledging to focus on economic growth, deregulate central power, promote FX convertibility, loosen control of investment and boost reforms of SOE in key industries such as electricity.

- Reserve Bank of Australia unveiled its policy meeting minutes from earlier this month when RBA cut rates to 2% as expected. The minutes were largely dovish, stating the delay in GDP pickup would lead to higher unemployment rate as well as anticipating terms of trade to fall further. RBA also pointed to the timing of recovery in non-mining investment as key to the economy and expressed concern over China property market. Most importantly, RBA said the lack of policy guidance in the statement does not limit scope for further easing - comment that led to selling in AUD and a rebound in S&P/ASX. AUD/USD fell over 30pips on the comments below $0.7960.

- NZD trading was also volatile once again, initially falling 20pips below 0.7360 on PPI data but then spiking on quarterly release from the RBNZ by over 50pips above 0.7420. RBNZ put 2-year inflation expectation at 1.85% V 1.80% prior - the first increase in a year - though 2-year GDP and 90-day bill rate expectations were revised a bit lower.

***Equities***
US equities / ADRs:
- MOMO: Reports Q1 +$0.05 v -$0.06 y/y, R$26.3M v $5.4M y/y; +20.9% afterhours
- TTWO: Reports Q4 $0.49 v $0.26e, R$428M v $461Me; Announces 10M share buyback authorization (about 12% of outstanding); +7.0% afterhours
- A: Reports Q2 $0.38 v $0.39e, R$963M v $993Me; -3.8% afterhours
- URBN: Reports Q1 $0.25 v $0.30e, R$739M v $760Me; -16.4% afterhours

Notable movers by sector:
- Consumer discretionary: Esprit Holdings 330.HK -2.7% (profit warning); Beiqi Foton Motor Co 600166.CN +3.5% (sales tax exemption for new energy vehicle); Bega Cheese BGA.AU -3.1% (lowers guidance); COFCO Tunhe Co 600737.CN +3.1%, China Foods 506.HK +3.7% (clarification on COFCO restructuring)
- Financials: China overseas Land 688.HK +1.9% (Apr result); PICC Group 1339.HK +1.5% (YTD premium income); Huatai Securities 601688.CN +10.0% (Hong Kong IPO)
- Technology: Hangzhou Hikvision Digital Technology Co 002415.CN +4.1% (cooperation with Alibaba); Samsung Electronics 005930.KR +2.3% (speculation on Galaxy S6 Edge Plus release)
- Industrials: GrainCorp GNC.AU +1.1% (to expand malt production capacity)
- Utilities: Sinohydro Group Ltd 601669.CN +3.9% (YTD new contracts)

>>> US After Hours Summary: GIGA +24.4%, MOMO +21.5%, TTWO +7.4%, URBN


After Hours Summary: GIGA +24.4%, MOMO +21.5%, TTWO +7.4%, URBN -15.3%, AMCN -3.8%, A -3.1% following earnings/guidance

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings: 
GIGA +24.4%, MOMO +21.5%, TTWO +7.4%, LAKE +4.2%, DWSN +2.6%

Companies trading higher in after hours in reaction to news: GIGA +21.1% co finalized a $10 mln multi-year production order for high performance YIG filters for a major aerospace company; co also reported earnings), BIOL +7.4% (announced Harold C. Flynn Jr. will become President and Chief Executive Officer, effective July 13, 2015), TTWO +7.4% (increased share repurchase authorization to 10 mln shares; co also reported earnings), TRQ +3.9% (announced Oyu Tolgoi shareholders sign agreement to progress the development of underground mine)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: URBN -15.3%, AMCN -3.8%, A -3.1%, NOAH -2.6%, CCIH -0.7%

Companies trading lower in after hours in reaction to news: EOX -13.4% (announced common stock offering with aggregate public offering size of $150 mln), RNDY -8.9% (announced a proposed underwritten secondary offering of 3.5 mln shares of its common stock owned by selling shareholders), ARP -5.8% (announced it has agreed to acquire natural gas producing properties in the Arkoma basin, from its parent company, Atlas Energy (ATLS), for $35.5 mln), MBI -5.7% (announced the sale of 27.25 mln shares of common stock, by funds affiliated with Warburg Pincus), LINE -4.8% (announced public offering of 16 mln units), BRG -2.9% (co has commenced a public offering of ~3.85 mln shares of its Class A common stock), SABR -2.3% (confirmed the public offering of 22 mln shares of common stock by existing stockholders affiliated with TPG Global, LLC and Silver Lake Management Company), CDW -1.5% (commenced public offering of 10 mln shares of common stock by selling shareholders) 

LesÉchos: droit de vote double: un élément de pouvoir pour l'Etat

L’Etat s’est doté d’un instrument de pouvoir avec le droit de vote double

L’Etat peut céder des actions sans réduire son influence. A la clef, un pactole potentiel de plus de 16 milliards d’euros.

l’actionnariat long terme et lutter contre le court-ter- misme de certains investisseurs, jugé néfaste. La généralisation du droit de vote double pour tout actionnaire détenant des titres au nominatif depuis plus de deux ans répond à cet objectif. C’est ainsi que les politiques ont justifié ce volet boursier dans la loi Florange, ins- piré, il est vrai, des traumatismes créés par les OPA sur Pechiney et sur Arcelor – qui ont conduit à la disparition de deux symboles de la France, voire de l’Europe indus- trielle. Voilà pour la théorie. Dans les faits, cet objectif affiché a déjà fait long feu. Le prétendu « outil de fidélisation des actionnai- res investis dans la durée » s’est transformé en instrument de pou- voir. Le premier gagnant est l’Etat actionnaire. Renault, Air France, Engie (ex-GDF Suez), Orange : le gouvernement a veillé au grain. Il n’a pas hésité à monter au capital quand cela s’avérait nécessaire pour atteindre une minorité de blocage. Aux limites du politiquement correct Chez Renault, il a voulu avant tout empêcher que le groupe passe en régime de droits de vote simple. Et de peur de ne pas peser assez à l’assemblée générale avec ses 15 % des droits de vote, il n’a pas hésité à investir jusqu’à 1,2 milliard d’euros pour faire grimper ses parts à 19,7 %. Peu importe le bras de fer avec la direction de Renault ou avec l’allié japonais Nissan, peu importe que cette montée au capital ne soit que temporaire (l’Etat s’est engagé à revendre ses titres après l’assem- blée générale), peu importe que la technique employée soit plutôt celle d’un financier que d’une auto- rité publique. L’enjeu est tel que l’Etat a bravé les foudres du politi- quement correct. Et reproduit la même stratégie. Chez Air France, aussi, il a acheté des actions avant l’AG, mais la dépense est moindre. Montant de l’acquisition : entre 33,15 et 45,9 millions pour 1,7 % de titres en plus, soit 17,5 % du capital. Grâce aux droits de vote double, le gouver- nement peut vendre des titres, sans réduire son poids dans les groupes dont il est actionnaire. Concrètement, c’est donc poten- tiellement le jackpot pour l’Etat, dont les participations cotées repré- sentaient, au 31 mars 2015, 80,7 mil- liards d’euros. Habilement utilisée, la loi Florange est un moyen de se constituer une jolie cagnotte. Dans une étude réalisée fin mars, Exane BNP Paribas a évalué la part du capital que le gouvernement pour- rait céder tout en maintenant son 80,7 MILLIARDS D’EUROS Le montant global des participations cotées de l’Etat, au 31 mars 2015. influence. Cela pourrait représen- ter – au maximum – 10 % du capital d’EDF, 11,7 % d’Engie, 10,7 % des actions d’Orange, 3 % d’Areva, 0,5 % d’ADP, 1,4 % de Safran, 6,7 % chez AirFranceetunpeuplusde6%de Renault. Au total, ces cessions de participations cotées lui permet- traient de dégager la bagatelle de 16,45 milliards d’euros (calculé au cours de clôture de mi-avril). Grâce aux droits de vote double, l’Etat est en mesure de gérer ses par- ticipations de façon plus active. D’ailleurs, pour récompenser l’actionnariat de long terme, il y a d’autres outils : les dividendes majorés, les plans d’attribution d’actions gratuites. On peut aussi encourager l’actionnariat salarié. L’homme d’affaires breton, Vin- cent Bolloré, premier actionnaire de Vivendi, a usé des mêmes armes que l’Etat pour asseoir son pouvoir dans le groupe de médias avec 14,5 % du capital. Le procédé est tel- lement habile que les Italiens s’en sont inspirés. A l’été 2014, les droits de vote double ont fait leur appari- tion dans la péninsule, alors qu’ils n’y avaient jamais eu droit de cité. L’Etat a indiqué que c’était pour récompenser l’actionnaire de long terme. Mais lui aussi détient de grosses participations dans de grandes entreprises cotées, comme l’électricien Enel, le pétrolier ENI, Finmeccanica, SNAM ou Terna. Xavier Huillard, patron de Vinci, n’a pas eu peur de mettre les points sur les « i » dans une interview mi- avril à Bloomberg : « Le seul intérêt des droits de vote est de permettre de prendre le contrôle des sociétés sans avoir à détenir une majorité des actions », a-t-il indiqué.

>>> US Close Dow+0,14% S&P+0,30% Nasdaq+0,60% Russell+1,09%


Closing Market Summary: Dow and S&P 500 Set New Record Closing Highs


The stock market kicked off the new trading week on an upbeat note. The Nasdaq Composite led the way, climbing 0.6%, while the Dow Jones Industrial Average (+0.1%) and S&P 500 (+0.3%) underperformed, but still registered new record closing highs at 18,298.88 and 2,129.20, respectively.

The first session of the week featured a range-bound opening hour that was followed by a steady advance. Heavily-weighted financials (+0.5%) and health care (+0.5%) displayed relative strength from the start while another influential group—technology (+0.4%)—climbed ahead of the market during the early afternoon.

The afternoon strength in the tech sector was partially due to gains among chipmakers. The PHLX Semiconductor Index advanced 1.0% with Altera (ALTR 46.93, +2.51) climbing 5.7% amid reports the company is once again discussing a potential deal with Intel (INTC 33.40, +0.41). Meanwhile, large cap tech names traded in mixed fashion, but that was masked by Apple's (AAPL 130.19, +1.42) 1.1% gain after activist investor Carl Icahn sent a letter to Apple Chief Executive Officer Tim Cook, pushing for a larger buyback, and saying Apple is worth $240/share at this time.

Elsewhere, the consumer discretionary sector (+0.4%) also outperformed with retailers contributing to the strength after ANN (ANN 46.40, +7.69) agreed to be acquired by Ascena Retail Group (ASNA 14.07, -0.14) for $47.00/share, representing a 21.4% premium to Friday's closing price.

In other M&A news, Endo Health (ENDP 80.77, -4.58) fell 5.4% after announcing the acquisition of Par Pharmaceutical for $8.05 billion. For its part, the health care sector (+0.5%) ended among the leaders with biotechnology making a contribution. The iShares Nasdaq Biotechnology ETF (IBB 360.30, +4.69) advanced 1.3%, helping the Nasdaq climb ahead of the benchmark index.

On the downside, consumer staples (-0.3%) and materials (-0.4%) spent the entire session in the red while the energy sector (-0.1%) recovered the bulk of its loss ahead of the close. The growth-sensitive group traded alongside crude oil, which showed intraday weakness, but returned to unchanged ($59.69/bbl) shortly after the end of the pit session.

It is worth noting that crude oil showed resilience even though the Dollar Index (94.20, +1.06) advanced 1.1% for the day. On a related note, Treasuries spent the session in a steady retreat, pushing the 10-yr yield higher by eight basis points to 2.22%.

Today's participation was well below average with fewer than 700 million shares changing hands at the NYSE floor.

Economic data was limited to the NAHB Housing Market Index for May, which fell to 54 from 56 while the Briefing.com consensus expected an increase to 57.

Tomorrow, April Housing Starts (consensus 1.019 million) and Building Permits (consensus 1.065 million) will be released at 8:30 ET.
  • Nasdaq Composite +7.2% YTD 
  • Russell 2000 +4.4% YTD 
  • S&P 500 +3.4% YTD 
  • Dow Jones Industrial Average +2.7% YTD

(BN) Drug Takeover Valuations Soar as Par Pharma Gains 300%: Real M&A


Drug Takeover Valuations Soar as Par Pharma Gains 300%: Real M&A
2015-05-18 20:15:56.203 GMT


(For a Real M&A column news alert: SALT REALMNA <GO>.)

By Tara Lachapelle
(Bloomberg) -- To see just how much drug-company valuations
have ballooned, check out Monday’s takeover of little-known
generics maker Par Pharmaceutical Holdings Inc.
Par was taken private in 2012 by TPG Capital for about $1.9
billion. Now it’s selling for more than quadruple that price to
Endo International Plc, another drugmaker. Endo’s stock fell 5.4
percent after it announced the deal, which is its largest and
most expensive. It’s valuing Par at about 66 times 2014 earnings
before interest, taxes, depreciation and amortization and 7.5
times revenue.
Takeover valuations are “going through the roof” in the
pharma and biotech industries, Frank Orthbandt, a London-based
analyst for Fitch Ratings, said in a phone interview. “The
expectation is that prices are continuing to rise and that we’re
coming to an end of this low-interest-rate period in the U.S.,
so you had better bite the bullet and buy now at a very high
valuation.”
Acquisition prices this year for pharmaceutical and
biotechnology companies such as Par are the highest relative to
Ebitda and revenue in at least 20 years, according to data
compiled by Bloomberg based on median multiples for deals. There
was a 63 percent jump in the median Ebitda multiple this year,
the biggest annual increase since 1998.

‘Selling Moment’

Private-equity firms such as TPG are using this as an
opportunity to exit their investments as growth-hungry strategic
buyers show a willingness to pay the rich multiples. Many
leading drugmakers are reeling from patent losses on what were
once their most lucrative products, so they’re paying up to
replenish their pipelines. Others are taking advantage of low
tax rates gained from moving their headquarters to places such
as Ireland.
“This is a selling moment if you’re a financial owner of
companies, and it is a buying and consolidation moment if you’re
a well-capitalized public company that has a stock that is
trading really well,” Marshall Sonenshine, chairman of New
York-based investment bank Sonenshine Partners LLC, said in an
interview on Bloomberg radio Monday.
Fitch Ratings cautioned in a report last month that
acquisitions of biotech companies with only experimental drugs
and no marketed products are risky at these prices and could
weaken the acquirers’ credit quality.
Treatment areas such as cancer, cardiovascular and rare
diseases are where suitable targets are scarce and thus seeing
particularly lofty takeover prices.
For the younger drug developers, it’s based on “a nebulous
calculation of potential peak sales,” Orthbandt of Fitch said.
“In those cases, you have to rely on a lot of assumptions.”

Par Value

Those types of transactions differ from Monday’s takeover
of Par, which does generate revenue. It will add about $1.2
billion of annual generic sales to help Endo overtake Sun
Pharmaceutical Industries Ltd. as the fifth-largest seller of
generic medicines, according to Elizabeth Krutoholow, an analyst
for Bloomberg Intelligence.
Endo said Monday that Par is one of the largest suppliers
of extended-release products -- which are harder to copy and
manufacture than regular generic medicines -- and it’s also been
growing in sterile injectables. Par’s expansion in those areas
may explain the large increase in the company’s value over the
past three years.
“Endo really made it clear during their call that the
injectable business has gotten far more useful and successful,
and also the extended-release business is really where we’re
seeing generics going,” she said. “I think that made Par more
valuable than before it went private.”

For Related News and Information:
Endo Buys Par Pharma for $8.05 Billion Amid Hunt for More Deals
Pharma’s Comeback Deals Keep Drug M&A on Track to Reach Records
Salix Gets Swept Into Pharma Frenzy as Premiums Soar: Real M&A
Real M&A columns: NI REALMNA <GO>
Top deal stories: DTOP <GO>

To contact the reporter on this story:
Tara Lachapelle in New York at +1-212-617-8911 or
tlachapelle@bloomberg.net
To contact the editors responsible for this story:
Beth Williams at +1-212-617-2307 or
bewilliams@bloomberg.net
Elizabeth Wollman

(ZH) The Last Two Times This Happened, Stocks Crashed...Another ZeroHedge Armageddon article...



The Last Two Times This Happened, Stocks Crashed


Are stocks disconnected from reality? Probably, according to Tobin’s Q, a rather elegant way to assess equity valuations developed by the late Nobel Prize-winning Yale economist James Tobin. Put simply, Tobin’s Q compares the total value of stock prices with the value of underlying assets such as plants, inventory, and equipment (i.e. replacement costs). Add up the value of the equity, then buy all the assets, and see if you have some cash left over. If you do, stocks were overvalued. 

We’ve looked at this on a number of occasions, most recently in January when we noted that the Q ratio was near peaks observed over most of history’s bull markets, and as Bloomberg reports, stocks are now more overvalued than at any time in history with the exception of the tech bubble and the 1929 highs.

Via Bloomberg:

If you sold every share of every company in the U.S. and used the money to buy up all the factories, machines and inventory, you’d have some cash left over. That, in a nutshell, is the math behind a bear case on equities that says prices have outrun reality.

 

The concept is embodied in a measure known as the Q ratio developed by James Tobin, a Nobel Prize-winning economist at Yale University who died in 2002. According to Tobin’s Q, equities in the U.S. are valued about 10 percent above the cost of replacing their underlying assets -- higher than any time other than the Internet bubble and the 1929 peak.

Here's a look at the chart:

The above should come as absolutely no surprise to regular readers. Indeed, corporate management teams have adopted policies that virtually ensure the value of their equity will far outrun the replacement costs of the underlying assets. 

As we’ve documented exhaustively — in fact, one might argue that it’s been the single most important narrative we’ve pushed this year — companies are taking advantage of record low borrowing costs and voracious demand for corporate bonds by issuing record amounts of debt. The problem: the proceeds aren’t going towards capex (i.e. future growth and productivity) but rather towards buybacks which not only inflate EPS but also management’s equity-linked compensation.

This means that while stocks climb ever higher thanks to a perpetual bid from price insensitive corporate management teams and investors (and central banks) frontrunning the buybacks (repurchase authorizations hit a record in April, so it’s not difficult to see what’s coming), productive assets deteriorate, jeopardizing top line growth and, in turn, the ability to service debt costs down the road. Here are a few graphics that tell the story

One may argue that “capex is higher than ever”, but that is slightly misleading because while it may be at its highest level on record in absolute terms, a look at the following pretty clearly indicates that buybacks have the momentum...

...and buybacks have officially reached escape velocity...

Here's more from Bloomberg:

The ratio’s doubling since 2009 to 1.10 is a symptom of companies diverting money from their businesses to the stock market, choosing buybacks over capital spending. Six years of zero-percent interest rates have similarly driven investors into riskier things like equities, elevating the paper value of assets over their tangible worth, he said.

 

Standard & Poor’s 500 Index members last year spent about 95 percent of their profits on buybacks and dividends, with stock repurchases exceeding $2 trillion since 2009, data compiled by S&P Dow Jones Indices show.

 

In the first four months of this year, almost $400 billion of buybacks were announced, with February, March and April ranking as three of the four busiest months ever, according to data compiled by Birinyi Associates Inc.

Spending by companies on plants and equipment is lagging behind. While capital investment also rose to a record in 2014, its growth was 11 percent over the last two years, versus 45 percent in buybacks, data compiled by Barclays Plc show.

 

With equity prices surging and investment growth failing to keep pace, the Q ratio has risen to 58 percent above its average of 0.70 since 1900, according to data compiled by Birinyi and the Federal Reserve on market and asset values for non-financial companies. Readings above 1 are considered by some to be too high and the ratio has exceeded that threshold only 12 percent of the time, mostly between 1995 to 2001.

So congratulations to the Fed and to corporate America. Thanks to a protracted period of ultra-low rates and a combination of corporate short-sightedness and greed, stock prices have been driven to their third-largest disconnect with underlying productive assets in history. 

>>> ANN sale to Ascena followed broad review of options with JPMorgan

DEAL REPORTER

ANN sale to Ascena followed broad review of options with JPMorgan

ANN INC. (NYSE: ANN) conducted a months-long review of available options before announcing Monday it will be acquired by Ascena Retail Group (NASDAQ: ASNA), and no significant disposals are expected in connection with the deal, according to executives from both companies.

In her opening remarks on the conference call held today (18 May) to discuss the deal, ANN CEO Kay Krill said the company's board spent the past several months conducting an extensive review of a wide range of options.

"The review was conducted with the assistance of our outside advisor, JPMorgan, and included evaluating among other things continued execution of the company's long-term plan as a standalone entity, potential transactions with strategic partners and private equity firms, potential acquisition opportunity and potential changes to our capital structure and payout policy, including expanded share repurchase and/or the initiation of a cash dividend," Krill said.

ANN's status as a target had been the subject of extensive speculation in recent months, with a published report in early May saying the company was in advanced talks for a sale to Golden Gate Capital. ANN was willing to look at an offer in the low USD 40-per-share area, and Bain Capital had withdrawn from bidding, according to that 6 May newswire report.

The sale to Ascena values ANN at USD 47 per share for an enterprise value of approximately USD 2bn. Ascena will fund the deal with approximately 80% cash, supported by committed financing of up to USD 2.4bn from Goldman Sachs and Guggenheim. The transaction is expected to close in the second half of 2015.

The transaction multiple is 7.7 times trailing 12-months EBITDA, which drops to 4.9 times when synergies are included, Ascena CEO David Jaffe said Monday.

During the Q&A session of the call, Goldman Sachs analyst Taposh Bari noted that Ascena sold some non-core assets after buying Charming Shoppes in 2012, and asked if there was a similar opportunity within ANN's portfolio.

"If there is, it's de minimis," CEO Jaffe replied.

In addition to Guggenheim and Goldman, Ascena is being advised by Proskauer Rose. Wachtell, Lipton, Rosen & Katz is advising ANN along with JPMorgan.